{"id":4875,"date":"2022-09-13T06:00:18","date_gmt":"2022-09-13T11:00:18","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=4875"},"modified":"2025-07-25T11:23:37","modified_gmt":"2025-07-25T16:23:37","slug":"nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306eSTARLIGHT\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u3078\u306e\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u7b2c 2 \u76f8 STARLIGHT \u8a66\u9a13\u306e 6 \u304b\u6708\u30c7\u30fc\u30bf\u306f 2023 \u5e74\u4e0a\u534a\u671f\u306b\u4e88\u5b9a<\/i><\/strong><\/p>

\u30c0\u30e9\u30b9<\/span><\/span>,\u00a02022 \u5e74 9 \u6708 13 \u65e5<\/span><\/span>\u00a0 \u2014 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u7db2\u819c\u5909\u6027\u75be\u60a3\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3059\u308b\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u540c\u793e\u306f\u672c\u65e5\u3001\u76f2\u76ee\u306e\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u305f\u3081\u306e\u5468\u56f2\u5149\u3067\u6d3b\u6027\u5316\u53ef\u80fd\u306a\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u5149\u907a\u4f1d\u5b66\u7684\u5358\u72ec\u7642\u6cd5\u3067\u3042\u308bMCO-010\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u5b8c\u5168\u767b\u9332\u3092\u767a\u8868\u3057\u305f\u3002 \u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306e\u5834\u5408\u3002\u7b2c 2 \u76f8 STARLIGHT \u8a66\u9a13\u306e 6 \u304b\u6708\u9593\u306e\u30c7\u30fc\u30bf\u306f 2023 \u5e74\u4e0a\u534a\u671f\u306b\u5f97\u3089\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>

\u201c\u300c\u6211\u3005\u306f\u3001\u3053\u308c\u307e\u3067\u306e\u524d\u81e8\u5e8a\u8a66\u9a13\u304a\u3088\u3073\u81e8\u5e8a\u8a66\u9a13\u304b\u3089\u306e\u78ba\u304b\u306a\u30c7\u30fc\u30bf\u306b\u88cf\u4ed8\u3051\u3089\u308c\u305fMCO-010\u306e\u6cbb\u7642\u53ef\u80fd\u6027\u306b\u671f\u5f85\u3092\u5bc4\u305b\u3066\u3044\u308b\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306eCEO\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300cMCO-010\u306e\u785d\u5b50\u4f53\u5185\u6ce8\u5c041\u56de\u6295\u4e0e\u306e\u5b89\u5168\u6027\u3068\u52b9\u679c\u3092\u8a55\u4fa1\u3059\u308b\u3053\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u88ab\u9a13\u8005\u767b\u9332\u3092\u308f\u305a\u304b2\u30f6\u6708\u3067\u5b8c\u4e86\u3067\u304d\u305f\u3053\u3068\u306f\u3001\u5e45\u5e83\u3044\u6cbb\u7642\u5fdc\u7528\u304c\u53ef\u80fd\u306a\u3053\u306e\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u306b\u304a\u3044\u3066\u3001\u307e\u305f\u4e00\u3064\u5927\u304d\u306a\u524d\u9032\u3068\u306a\u308a\u307e\u3059\u3002\u300d\u201c<\/p>

\u7b2c2\u76f8STARLIGHT\u975e\u76f2\u691c\u8a66\u9a13\uff08NCT05417126<\/a>\u672c\u7814\u7a76\u3067\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306e\u81e8\u5e8a\u7684\u307e\u305f\u306f\u907a\u4f1d\u7684\u8a3a\u65ad\u306b\u3088\u308a\u8996\u529b\u4f4e\u4e0b\u304c\u9032\u884c\u3057\u305f6\u540d\u306e\u88ab\u9a13\u8005\u3092\u767b\u9332\u3057\u305f\u3002\u672c\u7814\u7a76\u3067\u306f\u3001\u3059\u3079\u3066\u306e\u88ab\u9a13\u8005\u306b\u3001\u5f53\u793e\u304c\u5b9f\u65bd\u3057\u305f\u7b2c1\u76f8\u8a66\u9a13\u3067\u4f7f\u7528\u3057\u305f\u306e\u3068\u540c\u3058\u3001MCO-010\u306e\u5358\u56de\u785d\u5b50\u4f53\u5185\u6295\u4e0e\u91cf1.2E11gc\/\u773c\u3092\u6295\u4e0e\u3057\u305f\u3002\u00a02b<\/span>\u00a0\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306e\u7814\u7a76\u3002<\/p>

\u201c\u300c\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306f\u3001\u5927\u4eba\u306b\u3082\u5b50\u4f9b\u306b\u3082\u767a\u75c7\u3059\u308b\u5931\u660e\u306e\u539f\u56e0\u3068\u306a\u308b\u75be\u60a3\u3067\u3059\u3002\u6700\u3082\u4e00\u822c\u7684\u306a\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3067\u3042\u308a\u3001\u78ba\u7acb\u3055\u308c\u305f\u6cbb\u7642\u6cd5\u306f\u3042\u308a\u307e\u305b\u3093\u300d\u3068\u3001\u30ed\u30d0\u30fc\u30c8\u30fbZ\u30fb\u30a2\u30f3\u30c9\u30fb\u30ca\u30f3\u30b7\u30fc\u30fbJ\u30fb\u30b0\u30ea\u30fc\u30f3\u8a18\u5ff5\u8b1b\u5ea7\u6559\u6388\u3067\u773c\u79d1\u5b66\u6559\u6388\u306e\u30d0\u30a4\u30ed\u30f3\u30fb\u30e9\u30e0\u533b\u5e2b\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u00a0\u30de\u30a4\u30a2\u30df\u5927\u5b66<\/span>\u00a0\u307e\u305f\u3001\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u306e\u6cbb\u9a13\u8cac\u4efb\u533b\u5e2b\u3082\u52d9\u3081\u3066\u3044\u307e\u3059\u3002\u300cMCO-010\u306f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u304a\u3088\u3073\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306e\u8996\u6a5f\u80fd\u6539\u5584\u306b\u52b9\u679c\u304c\u3042\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u3001\u672c\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u3092\u697d\u3057\u307f\u306b\u3057\u3066\u3044\u307e\u3059\u3002\u300d\u201c<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306f\u72ec\u81ea\u306e\u6280\u8853\u3092\u4f7f\u7528\u3057\u3066\u3044\u307e\u3059\u00a0AAV2<\/i>\u00a0MCO\u907a\u4f1d\u5b50\u3092\u7db2\u819c\u7d30\u80de\u306b\u5c0e\u5165\u3057\u3001\u69d8\u3005\u306a\u8272\u74b0\u5883\u4e0b\u3067\u306e\u8996\u899a\u3092\u53ef\u80fd\u306b\u3059\u308b\u30d9\u30af\u30bf\u30fc\u3002\u3053\u306e\u6cbb\u7642\u6cd5\u306f\u3001\u4ed6\u306e\u6a5f\u5668\u3084\u51e6\u7f6e\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u3067\u5358\u56de\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u3068\u3057\u3066\u6295\u4e0e\u3055\u308c\u308b\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u304a\u3088\u3073\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u3068\u3057\u3066FDA\u304b\u3089\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u540c\u6642\u306bNanoscope\u793e\u306e\u7b2c1\u76f8\u81e8\u5e8a\u8a66\u9a13\u3067\u8a55\u4fa1\u3055\u308c\u3066\u3044\u308b\u3002\u00a02b<\/span>\u00a0RP\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fRESTORE\u8a66\u9a13\u3002\u8a66\u9a13\u7d50\u679c\u30822023\u5e74\u4e0a\u534a\u671f\u306b\u4e88\u5b9a\u3055\u308c\u3066\u3044\u308b\u3002<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<\/b><\/div>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u3063\u3066\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306b\u306f\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u3002\u540c\u793e\u306e\u4e3b\u8981\u958b\u767a\u5019\u88dc\u3067\u3042\u308bMCO-010\u306f\u73fe\u5728\u3001\u7b2c1\u76f8\u81e8\u5e8a\u8a66\u9a13\u6bb5\u968e\u306b\u3042\u308b\u3002\u00a02b<\/span>\u00a0\u7c73\u56fd\u306b\u304a\u3051\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u30de\u30b9\u30af\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08NCT04945772<\/a>\uff09\u30c8\u30c3\u30d7\u30e9\u30a4\u30f3\u30c7\u30fc\u30bf\u306f2023\u5e74\u4e0a\u534a\u671f\u306b\u4e88\u60f3\u3055\u308c\u308b\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8\u8a66\u9a13\u3092\u958b\u59cb\u3057\u305f\uff08NCT05417126<\/a>\uff09\u3002 MCO-010 \u306f\u3001RP \u304a\u3088\u3073 Stargardt \u306b\u5bfe\u3057\u3066 FDA \u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306e\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001\u5730\u7406\u7684\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u30ec\u30fc\u30b6\u30fc\u306b\u3088\u308b MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>

\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b>
\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba
212-600-1902
Nanoscope@argotpartners.com<\/a><\/p>

\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023 DALLAS,\u00a0Sept. 13, 2022\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023. \u201cWe are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies,\u201d said\u00a0Sulagna Bhattacharya, CEO of Nanoscope. \u201cCompleting the quick two-month enrollment of this Phase 2 trial, which will evaluate the safety […]<\/p>\n","protected":false},"author":6,"featured_media":4876,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-4875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T11:00:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T16:23:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease\",\"datePublished\":\"2022-09-13T11:00:18+00:00\",\"dateModified\":\"2025-07-25T16:23:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"},\"wordCount\":464,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"datePublished\":\"2022-09-13T11:00:18+00:00\",\"dateModified\":\"2025-07-25T16:23:37+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13STARLIGHT\u306b\u304a\u3051\u308b\u88ab\u9a13\u8005\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2022-09-13T11:00:18+00:00","article_modified_time":"2025-07-25T16:23:37+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease","datePublished":"2022-09-13T11:00:18+00:00","dateModified":"2025-07-25T16:23:37+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"},"wordCount":464,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","url":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13STARLIGHT\u306b\u304a\u3051\u308b\u88ab\u9a13\u8005\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","datePublished":"2022-09-13T11:00:18+00:00","dateModified":"2025-07-25T16:23:37+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=4875"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4875\/revisions"}],"predecessor-version":[{"id":9244,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4875\/revisions\/9244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/4876"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=4875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=4875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=4875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}